Active substance
Metronidazole
- SFDA 51
- US FDA 94
- Health Canada 13
- US price lines 7
- NHS prices 10
- WHO EML 2
- Safety 20
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AMRIZOLE 250 Mg TABLET | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 9.55 | Generic · Prescription | ALAMRIAH FOR PHARMACEUTICALS INDUSTRIES | Valid |
| AMRIZOLE 500MG VAGINAL SUPPOSITORIES | 500 mg | Suppository · Vaginal use | 5 Blister | SAR 7.80 | Generic · Prescription | ALAMRIAH FOR PHARMACEUTICALS INDUSTRIES | Valid |
| AMRIZOLE INJ 500MG-100ML BOTTLE | 5 mg/ml | Solution · Intravenous use | 1 Bottle | SAR 9.50 | Generic · Prescription | ALAMRIAH FOR PHARMACEUTICALS INDUSTRIES | Valid |
| AMRIZOLE SUSP 125MG-5ML | 25 mg/ml | Suspension · Oral use | 1 Bottle | SAR 6.55 | Generic · Prescription | ALAMRIAH FOR PHARMACEUTICALS INDUSTRIES | Valid |
| ANAZOL | 500 mg | Film-coated tablet · Oral use | 130 Blister | SAR 88.55 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ANAZOL | 250 mg | Film-coated tablet · Oral use | 130 Blister | SAR 41.95 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ANAZOL 125MG-5ML SUSP. | 25 mg/ml | Suspension · Oral use | 1 Bottle | SAR 6.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ANAZOL 200MG-5ML SUSPENSION | 40 mg/ml | Suspension · Oral use | 1 Bottle | SAR 10.05 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ANAZOL 250 MG F.C. TAB | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 6.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ANAZOL 500 MG F.C. TAB | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 14.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| FLAGYL 250MG TAB | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 10.05 | NCE · Prescription | sanofi-aventis | Valid |
| FLAGYL 500MG SCORED TABS | 500 mg | Film-coated tablet · Oral use | 14 Blister | SAR 19.15 | Generic · Prescription | sanofi-aventis | Valid |
| FLAZOL 125MG-5ML ORAL SUSP | 25 mg/ml | Suspension · Oral use | 1 Bottle | SAR 9.25 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| FLAZOL 500MG TAB | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 19.90 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| METRONIDAZOLE 500MG-100ML INFUSION | 5 mg/ml | Solution for infusion · Intravenous use | 1 Bottle | SAR 8.15 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| METRONIDAZOLE 500MG/100ML INTRAVENOUS INFUSION | 5 mg/ml | Solution for infusion · Intravenous use | 1 Bottle | SAR 10.00 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| MOPIZALE 500MG/100ML SOLUTION FOR INFUSION | 5 mg/ml | Solution for infusion · Intravenous use | 10 Vial | SAR 68.00 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Metronidazole intravenous infusion | 5 mg/ml | Solution for infusion · Intravenous use | 1 Bottle | SAR 10.50 | Generic · Prescription | B. BRAUN | Valid |
| Metrosol | 5 mg/ml | Solution for infusion · Intravenous use | 1 Bottle | SAR 10.00 | Generic · Prescription | AL RAZI PHARMA INDUSTRIES | Valid |
| NEGAZOLE | 250 mg | Film-coated tablet · Oral use | 100 Blister | SAR 26.00 | Generic · Prescription | GULF PHARMACEUTICAL INDUSTIRES- JULPHAR | Valid |
| NEGAZOLE 250MG TAB. | 250 mg | Tablet · Oral use | 20 Blister | SAR 5.20 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| NEGAZOLE 500MG TAB. | 500 mg | Tablet · Oral use | 20 Blister | SAR 12.05 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Nuvessa | 1.3 % | Gel · Vaginal use | 1 Applicator | SAR 75.90 | NCE · Prescription | Exeltis USA Inc | Valid |
| RIAZOLE | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 19.90 | Generic · Prescription | RIYADH PHARMA | Valid |
| ROZEX GEL 0.75% W-W | 0.75 % | Gel · Topical | 1 Tube | SAR 19.75 | Generic · Prescription | GALDERMA | Valid |
26 more — full table
Indications — CHI Daman Drug Formulary
ANTIBIOTIC SURGICAL PROPHYLAXIS; BACTERIAL GENITAL TRACT INFECTIONS; BACTERIAL SKIN INFECTIONS - GAS GANGRENE; BACTERIAL SKIN INFECTIONS - NECROTIZING FASCIITIS; BACTERIAL SKIN INFECTIONS - SURGICAL SITE INFECTIONS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - CLOSTRIDIUM DIFFICILE INFECTIONS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-EVIDENCE BASED FIRST LINE TREATMENT STRATEGY; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-SALVAGE THERAPIES; BALANTIDIASIS; BLASTOCYSTIS; CROHN'S DISEASE; DENTAL ABSCESS; DIENTAMOEBA; ENTAMOEBA HISTOLYTICA INFECTION; GIARDIA LAMBLIA INFECTION; INTRA-ABDOMINAL INFECTIONS; LICHEN PLANUS; LIVER CIRRHOSIS; NECROTIZING PERIODONTITIS AND NECROTIZING ULCERATIVE GINGIVITIS; OSTEOMYELITIS; PERICORONITIS; PERITONITIS; TRAVELLER'S DIARRHEA; TRICHOMONAS VAGINALIS; ULCERATIVE COLITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| FLAGYL I.V. RTU IN PLASTIC CONTAINER | 500MG/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 24 Dec 1981 |
| METRONIDAZOLE IN PLASTIC CONTAINER | 500MG/100ML | injectable · injection | HOSPIRA | Prescription | 18 Nov 1983 |
| METRONIDAZOLE | 250MG | tablet · oral | TEVA PHARMS USA | Prescription | 6 Dec 1984 |
| METRONIDAZOLE | 500MG | tablet · oral | PLIVA | Prescription | 6 Dec 1984 |
| METRONIDAZOLE | 250MG | tablet · oral | WATSON LABS | Prescription | 20 Dec 1984 |
| METRONIDAZOLE | 500MG | tablet · oral | WATSON LABS INC | Prescription | 8 Feb 1985 |
| METRONIDAZOLE | 250MG; 500MG; 125MG | tablet · oral | INNOGENIX | Prescription | 16 Jul 1986 |
| FLAGYL | 375MG | capsule · oral | PFIZER | Prescription | 3 May 1995 |
| METROCREAM | 0.75% | cream · topical | GALDERMA LABS LP | Prescription | 20 Sep 1995 |
| NORITATE | 1% | cream · topical | BAUSCH | Prescription | 26 Sep 1997 |
| METROLOTION | 0.75% | lotion · topical | GALDERMA LABS LP | Prescription | 24 Nov 1998 |
| METRONIDAZOLE | 375MG | capsule · oral | CHARTWELL RX | Prescription | 29 Jan 2004 |
| METRONIDAZOLE | 0.75% | cream · topical | FOUGERA PHARMS | Prescription | 28 May 2004 |
| VANDAZOLE | 0.75% | gel · vaginal | TEVA PHARMS | Prescription | 20 May 2005 |
| METROGEL | 1% | gel · topical | GALDERMA LABS LP | Prescription | 30 Jun 2005 |
| METRONIDAZOLE | 0.75% | lotion · topical | FOUGERA PHARMS | Prescription | 24 May 2006 |
| METRONIDAZOLE | 0.75% | gel · topical | FOUGERA PHARMS | Prescription | 6 Jun 2006 |
| METRONIDAZOLE | 0.75% | gel · topical | ENCUBE | Prescription | 13 Jul 2006 |
| METRONIDAZOLE | 0.75% | gel · topical | TARO | Prescription | 18 Jul 2006 |
| METRONIDAZOLE | 0.75% | cream · topical | COSETTE PHARMS NC | Prescription | 19 Dec 2007 |
| METRONIDAZOLE | 250MG; 500MG | tablet · oral | ALEMBIC PHARMS LTD | Prescription | 13 Mar 2009 |
| METRONIDAZOLE | 375MG | capsule · oral | ALEMBIC | Prescription | 23 Jun 2009 |
| METRONIDAZOLE | 0.75% | gel · topical | COSETTE PHARMS NC | Prescription | 19 Jan 2011 |
| METRONIDAZOLE | 250MG; 500MG | tablet · oral | UNICHEM | Prescription | 22 Jan 2014 |
| NUVESSA | 1.3% | gel · vaginal | ALEMBIC THERAP | Prescription | 24 Mar 2014 |
69 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-METRONIDAZOLE | 02248562 | 500 MG | CAPSULE · ORAL | APOTEX INC |
| APO-METRONIDAZOLE TABLETS | 00545066 | 250 MG | TABLET · ORAL | APOTEX INC |
| AURO-METRONIDAZOLE | 02470284 | 500 MG | CAPSULE · ORAL | AURO PHARMA INC |
| M-METRONIDAZOLE | 02519755 | 500 MG | CAPSULE · ORAL | MANTRA PHARMA INC |
| METROGEL 0.75% | 02092832 | 0.75 % | GEL · TOPICAL | GALDERMA CANADA INC. |
| METROGEL 1% | 02297809 | 1 % | GEL · TOPICAL | GALDERMA CANADA INC. |
| METRONIDAZOLE | 02518767 | 500 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| METRONIDAZOLE | 02534592 | 500 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| METRONIDAZOLE INJECTION, USP | 00870420 | 5 MG / ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| MINT-METRONIDAZOLE | 02535807 | 250 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| NIDAGEL | 02125226 | 0.75 % / W/W | GEL · VAGINAL | BAUSCH HEALTH, CANADA INC. |
| NORITATE | 02156091 | 1 % / W/W | CREAM · TOPICAL | BAUSCH HEALTH, CANADA INC. |
| PMS-METRONIDAZOLE | 00783137 | 500 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LIKMEZ 500 MG/5 ML SUSPENSION | $2.60822 | per ML | 23 Sep 2026 |
| US NADAC | LIKMEZ 500 MG/5 ML SUSPENSION | $2.60124 | per ML | 23 Sep 2026 |
| US NADAC | METRONIDAZOLE 0.75% CREAM | $0.2571 | per GM | 23 Sep 2026 |
| US NADAC | METRONIDAZOLE 0.75% LOTION | $1.81728 | per ML | 23 Sep 2026 |
| US NADAC | METRONIDAZOLE 250 MG TABLET | $0.10165 | per EA | 23 Sep 2026 |
| US NADAC | METRONIDAZOLE 375 MG CAPSULE | $7.30796 | per EA | 21 Jan 2026 |
| US NADAC | METRONIDAZOLE 500 MG TABLET | $0.10426 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Metronidazole 0.75% cream | £12.35 | 50 gram | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 0.75% gel | £5.98 | 15 gram | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 0.75% gel | £22.63 | 40 gram | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 0.75% vaginal gel | £4.31 | 40 gram | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 1g suppositories | £23.06 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 200mg tablets | £0.96 | 21 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 200mg/5ml oral suspension | £44.92 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 400mg tablets | £1.02 | 21 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 500mg suppositories | £15.18 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Metronidazole 500mg tablets | £8.82 | 21 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.5.1. Antiamoebic and antigiardiasis medicines · core
Amoebiasis
Oral > Liquid: 200 mg per 5 mL (as benzoate) | Parenteral > General injections > unspecified: 500 mg in 100 mL vial | Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg - 6.2.1. Access group antibiotics · core
First choice: Trichomoniasis; First choice: Intestinal infections due to Clostridioides difficile; First choice: Necrotising fasciitis; First choice: Other specified prophylactic measures (co-prescribed with cefazolin); First choice: Peritoneal abscess (mild-moderate) (co-prescribed with cefotaxime); First choice: Peritoneal abscess (severe) (co-prescribed with cefotaxime); First choice: Peritonitis (mild-moderate) (co-prescribed with cefotaxime); First choice: Peritonitis (severe) (co-prescribed with cefotaxime); First choice: Peritoneal abscess (mild-moderate) (co-prescribed with ceftriaxone); First choice: Peritoneal abscess (severe) (co-prescribed with ceftriaxone); First choice: Peritonitis (mild-moderate) (co-prescribed with ceftriaxone); First choice: Peritonitis (severe) (co-prescribed with ceftriaxone); Second choice: Peritoneal abscess (mild-moderate) (co-prescribed with ciprofloxacin); Second choice: Peritonitis (mild-moderate) (co-prescribed with ciprofloxacin)
Oral > Liquid: 200 mg per 5 mL (as benzoate) | Local > Rectal > Suppository: 500 mg; 1 g | Parenteral > General injections > unspecified: 500 mg per 100 mL in vial | Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg | Local > Rectal > Suppository: 500 mg (EML); 1 g (EML)
Safety signals and safety-related labeling changes
- US FDA 23 Apr 2026 METRO I.V. IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 24 Jun 2025 FLAGYL I.V. RTU IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 31 Mar 2025 HELIDAC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions - US FDA 31 Mar 2025 PYLERA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 Mar 2025 METRONIDAZOLE IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 8 Jul 2024 FLAGYL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 8 Jul 2024 FLAGYL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 8 Jul 2024 FLAGYL ER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 8 Jul 2024 METRONIDAZOLE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 8 Jul 2024 METRONIDAZOLE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 8 Jul 2024 METRONIDAZOLE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 8 Jul 2024 METRONIDAZOLE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 8 Jul 2024 METRONIDAZOLE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 8 Jul 2024 LIKMEZ — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Mar 2022 METROGEL — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations
Combinations containing Metronidazole
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.